Liu Shen & Associates

Ke Mou and Stephen Zou of Liu Shen & Associates outline China’s evolving framework on pharmaceutical intellectual property protection, examining how data exclusivity, patent term extension, patent linkage, and enforcement mechanisms support innovation

Chunyu Cui and Ziqing Wu of Liu Shen & Associates say recent trends in China’s intellectual property courts indicate alignment with international standards and send a clear signal to the global market

Wenjing Zhu of Liu, Shen & Associates explains how China’s administrative adjudication system is reshaping patent enforcement, offering faster, cost-effective, and technically expert resolutions for patentees, while preserving rights to pursue court remedies

Hongbo Jia of Liu, Shen & Associates examines recent Supreme People’s Court cases that reshape Chinese patent litigation in addressing damages, patent validity, and pre-litigation injunctions, with important implications for multinational businesses

Ran Wang of Liu, Shen & Associates outlines the guidance the cited cases offer on issues such as patent evaluation reports, infringement judgments after invalidation, use environment features, and amendment rules

Guanyang Yao of Liu, Shen & Associates reviews several Chinese court rulings on standard-essential patent disputes, including Panasonic v Oppo, and the growing judicial focus on mediation and comparable licences over top-down rate setting